# Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

> **NCT04929236** · PHASE3 · RECRUITING · sponsor: **Octapharma** · enrollment: 30 (estimated)

## Conditions studied

- Pediatric Chronic Inflammatory Demyelinating Polyneuropathy

## Interventions

- **DRUG:** Panzyga

## Key facts

- **NCT ID:** NCT04929236
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04929236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04929236, "Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04929236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*